NCT06623630View on ClinicalTrials.gov

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

March 31, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Cyclophosphamide

Standard of care

DRUG

Ciltacabtagene Autoleucel

Standard of care

RADIATION

Total body irradiation

Radiation doses delivered to the entire body

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

American Cancer Society, Inc.

OTHER

collaborator

Cures Within Reach

OTHER

lead

Washington University School of Medicine

OTHER